Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade B-Cell Lymphoma, Not Otherwise Specified: early-phase trial registry
3 of 8 indexed High Grade B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
High Grade B-Cell Lymphoma, Not Otherwise Specified: 8 US clinical trials tracked, 3 recruiting.
High Grade B-Cell Lymphoma, Not Otherwise Specified is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.
Enrollment posture brief
Registry condition high-grade-b-cell-lymphoma-not-otherwise-specified
OPEN 3 | RECR 38% | LATE 0 | EARLY 8 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
High Grade B-Cell Lymphoma, Not Otherwise Specified lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade B-Cell Lymphoma, Not Otherwise Specified on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade B-Cell Lymphoma, Not Otherwise Specified is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High Grade B-Cell Lymphoma, Not Otherwise Specified research.
Northwestern University accounts for 2 of 8 trials (25%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most High Grade B-Cell Lymphoma, Not Otherwise Specified trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
High Grade B-Cell Lymphoma, Not Otherwise Specified research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01371630
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT04231877
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
NCT03984448
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
NCT03038672
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
NCT02153580
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
NCT05202782
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
NCT03742258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade B-Cell Lymphoma, Not Otherwise Specified records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade B-Cell Lymphoma, Not Otherwise Specified trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade B-Cell Lymphoma, Not Otherwise Specified page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 High Grade B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwestern University sponsors the most High Grade B-Cell Lymphoma, Not Otherwise Specified trials on record, review their full trial history before evaluating a specific study. See Northwestern University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade B-Cell Lymphoma, Not Otherwise Specified condition card totals 8 registered trials; most-linked intervention Cyclophosphamide; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.